Heska Corp (HSKA)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Kevin S. Wilson
Employees:
347
3760 ROCKY MOUNTAIN AVENUE, LOVELAND, CO 80538
9704937272

Heska Corp. engages in the research, development and manufacture of veterinary products. The company operates through two segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals & Products. The Core Companion Animal Health segment supplies blood testing instruments, digital imaging software, heartworm diagnostic tests and preventive products, allergy immunotherapy products, and allergy testing. The Other Vaccines, Pharmaceuticals and Products segment develops and distributes vaccines and pharmaceutical products. Its solutions include, dri-chem 4000, 7000, hematrue, element ht5, element i and solo step heartworm. Heska was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.

Data derived from most recent annual or quarterly report
Market Cap 1.033 Billion Shares Outstanding10.786 Million Avg 30-day Volume 78.694 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.19
Price to Revenue5.5052 Debt to Equity0.2334 EBITDA-132 Thousand
Price to Book Value3.3144 Operating Margin-5.2183 Enterprise Value1.343 Billion
Current Ratio6.729 EPS Growth-0.649 Quick Ratio5.078
1 Yr BETA 1.0998 52-week High/Low 275.94 / 79.96 Profit Margin-5.04
Operating Cash Flow Growth-334.3807 Altman Z-Score5.3737 Free Cash Flow to Firm -104.43 Million
Earnings Report2022-08-02
View SEC Filings from HSKA instead.

View recent insider trading info

Heska Corp YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding HSKA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HSKA BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-06-02 by GRASSMAN CATHERINE
  • 4: filed on 2022-05-06 by SVEEN DAVID E.
  • 4: filed on 2022-05-06 by LARSON SHARON J.
  • 4: filed on 2022-05-06 by HASENMAIER JOACHIM A.
  • 4: filed on 2022-05-06 by HUMPHREY SCOTT
  • 4: filed on 2022-05-06 by FURLONG MARK F
  • 4: filed on 2022-05-06 by DAVIS STEPHEN L
  • 4: filed on 2022-05-06 by ANTIN ROBERT L
  • 4: filed on 2022-03-09 by WISNEWSKI NANCY
  • 4: filed on 2022-03-09 by GRASSMAN CATHERINE

    • Events (8k)

  • 8-K: filed on 2022-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-05:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-02-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-22:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2021-11-04:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2021-11-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-06-10:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-05-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2021-05-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GRASSMAN CATHERINE EVP, CFO

    • Officer
    		 9,140 2022-06-01 4

    ANTIN ROBERT L

    • Director
    		 2,189 2022-05-04 1

    FURLONG MARK F

    • Director
    		 4,726 2022-05-04 1

    LARSON SHARON J.

    • Director
    		 8,608 2022-05-04 2

    DAVIS STEPHEN L

    • Director
    		 3,053 2022-05-04 1

    SVEEN DAVID E.

    • Director
    		 43,081 2022-05-04 2

    HUMPHREY SCOTT

    • Director
    		 6,881 2022-05-04 1

    HASENMAIER JOACHIM A.

    • Director
    		 2,004 2022-05-04 1

    WISNEWSKI NANCY CHIEF OPERATING OFFICER

    • Officer
    		 71,032 2022-03-07 4

    WILSON KEVIN S. CEO AND PRESIDENT

    • Officer
    • Director
    		 463,120 2022-03-07 5

    EYL STEVEN M. EVP, CCO & PRES.SCIL

    • Officer
    		 22,702 2022-03-07 2

    BAKER ELEANOR F. EVP, MANAGING DIR. & COO, SCIL

    • Officer
    		 3,395 2022-03-03 3

    SVEEN CHRISTOPHER D. CAO & GENERAL COUNSEL

    • Officer
    		 4,004 2022-02-28 2

    AROESTY JASON D EVP, INTERNATIONAL DIAGNOSTICS

    • Officer
    		 0 2020-11-27 0

    TROWBRIDGE BONNIE J.

    • Director
    		 4,089 2020-11-09 0

    NAPOLITANO JASON A CHIEF STRATEGY OFFICER

    • Officer
    		 62,799 2019-12-30 0

    GORDON G IRWIN

    • Director
    		 25,074 2018-11-29 0

    LIPPINCOTT ROD EVP, COMP. ANIMAL HEALTH SALES

    • Officer
    		 8,573 2018-08-31 0

    ASAKOWICZ STEVE EVP, COMP. ANIMAL HEALTH SALES

    • Officer
    		 8,400 2018-08-27 0

    WRENN CAROL

    • Director
    		 5,249 2018-05-03 0

    MCGINLEY MICHAEL J PRESI, BIOLOGIC. & PHARM.

    • Officer
    		 86,776 2018-03-17 0

    MCMAHON JOHN VP, CHIEF FINANCIAL OFFICER

    • Officer
    		 68 2017-08-30 0

    GRIEVE ROBERT B EXECUTIVE CHAIR

    • Officer
    • Director
    		 106,331 2015-08-28 0

    AYLESWORTH WILLIAM A

    • Director
    		 37,397 2015-03-09 0

    BENT MICHAEL A V.P.ACTG. OFFICER & CONTROLLER

    • Officer
    		 9,773 2012-12-28 0

    APERFINE JOSEPH EVP, SALES AND MARKETING

    • Officer
    		 0 2012-12-19 0

    ZACHARA CLAUDINE

    • VP, MARKETING
    		 0 2012-12-19 0

    CMC MASTER FUND, L.P.

    CMC MASTER FUND PARTNERS, LLC

    • 10% Owner
    		 No longer subject to file 2012-10-09 0

    SASEN JOHN F

    • Director
    		 0 2012-05-08 0

    EIO PETER

    • Director
    		 0 2012-05-08 0

    MCCORMICK LOUISE L.

    • Director
    		 0 2012-05-08 0

    CMC MASTER FUND, L.P.

    CMC MASTER FUND PARTNERS, LLC

    C.M. CAPITAL ADVISORS, LLC

    C.M. CAPITAL CORP

    • 10% Owner
    		 579,045 2012-02-15 0

    SNODGRASS GERALD L VP, SALES

    • Officer
    		 0 2009-11-10 0

    PACIFIC COAST INVESTORS LTD

    • 10% Owner
    		 No longer subject to file 2009-08-25 0

    FLANDERS JOHN R V.P., GENERAL COUNSEL

    • Officer
    		 32,500 2008-11-25 0

    CHARTER VENTURES II, L.P.

    CHARTER VENTURES

    • 10% Owner
    		 No longer subject to file 2008-06-20 0

    RITTER JOSEPH H EVP, GLOBAL BUS. OPERATIONS

    • Officer
    		 0 2007-12-31 0

    DOLAN A BARR

    • Director
    		 40,167 2007-05-04 0

    GILSON TODD M VP, MARKETING

    • Officer
    		 0 2007-03-09 0

    DEMARSE ELISABETH H

    • Director
    		 1,328 2006-11-20 0

    STEVENSON LYNNOR B

    • Director
    		 330,124 2006-03-29 0

    CHARTER LIFE SCIENCES I-IV LLC

    • 10% Owner
    		 0 2006-01-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    GRASSMAN CATHERINE - Officer EVP, CFO

    		2022-06-02 16:13:56 -0400 2022-06-01 F 398 $99.71 d 9,140 direct -2.02 -5.7302 1.8757 4 -5.7302 6

    ANTIN ROBERT L - Director

    		2022-05-06 11:39:56 -0400 2022-05-04 A 1,107 a 2,189 direct -10.7993 -12.5446 -13.219 0.1884 16 -16.4716 30

    DAVIS STEPHEN L - Director

    		2022-05-06 11:43:28 -0400 2022-05-04 A 1,107 a 2,553 direct -10.7993 -12.5446 -13.219 0.1884 16 -16.4716 30

    FURLONG MARK F - Director

    		2022-05-06 11:45:44 -0400 2022-05-04 A 1,107 a 4,726 direct -10.7993 -12.5446 -13.219 0.1884 16 -16.4716 30

    HUMPHREY SCOTT - Director

    		2022-05-06 11:47:54 -0400 2022-05-04 A 1,107 a 6,881 direct -10.7993 -12.5446 -13.219 0.1884 16 -16.4716 30

    HASENMAIER JOACHIM A. - Director

    		2022-05-06 11:49:56 -0400 2022-05-04 A 1,107 a 2,004 direct -10.7993 -12.5446 -13.219 0.1884 16 -16.4716 30

    LARSON SHARON J. - Director

    		2022-05-06 11:52:47 -0400 2022-05-04 A 1,107 a 8,608 direct -10.7993 -12.5446 -13.219 0.1884 16 -16.4716 30

    SVEEN DAVID E. - Director

    		2022-05-06 11:55:06 -0400 2022-05-04 A 1,107 a 21,653 direct -10.7993 -12.5446 -13.219 0.1884 16 -16.4716 30

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    HESKA CORP HSKA 2022-06-28 22:15:04 UTC 1.1666 0.4034 200000
    HESKA CORP HSKA 2022-06-28 21:45:03 UTC 1.1666 0.4034 200000
    HESKA CORP HSKA 2022-06-28 21:15:03 UTC 1.1666 0.4034 200000
    HESKA CORP HSKA 2022-06-28 20:45:03 UTC 1.1666 0.4034 200000
    HESKA CORP HSKA 2022-06-28 20:15:04 UTC 1.1666 0.4034 200000
    HESKA CORP HSKA 2022-06-28 19:45:03 UTC 1.1666 0.4034 200000
    HESKA CORP HSKA 2022-06-28 19:15:03 UTC 1.1666 0.4034 200000
    HESKA CORP HSKA 2022-06-28 18:45:03 UTC 1.1754 0.3946 200000
    HESKA CORP HSKA 2022-06-28 18:15:04 UTC 1.1754 0.3946 200000
    HESKA CORP HSKA 2022-06-28 17:45:03 UTC 1.1754 0.3946 200000
    HESKA CORP HSKA 2022-06-28 17:15:03 UTC 1.1754 0.3946 200000
    HESKA CORP HSKA 2022-06-28 16:45:06 UTC 1.168 0.402 200000
    HESKA CORP HSKA 2022-06-28 16:15:03 UTC 1.168 0.402 200000
    HESKA CORP HSKA 2022-06-28 15:45:03 UTC 1.168 0.402 200000
    HESKA CORP HSKA 2022-06-28 15:15:03 UTC 1.168 0.402 200000
    HESKA CORP HSKA 2022-06-28 14:45:03 UTC 1.168 0.402 200000
    HESKA CORP HSKA 2022-06-28 14:15:04 UTC 1.168 0.402 200000
    HESKA CORP HSKA 2022-06-28 13:45:03 UTC 1.168 0.402 200000
    HESKA CORP HSKA 2022-06-28 13:15:03 UTC 1.168 0.402 200000
    HESKA CORP HSKA 2022-06-28 12:45:03 UTC 1.168 0.402 200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    RBB Fund, Inc.- Boston Partners Long/Short Equity Fund HSKA -773.0 shares, $-109766.0 2022-02-28 N-PORT
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund HSKA -2148.0 shares, $-295521.84 2022-01-31 N-PORT
    NORTHERN LIGHTS FUND TRUST II- Invenomic Fund HSKA -19604.0 shares, $-2153303.36 2022-04-30 N-PORT

    Elevate your investments